All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
All you need to know about VIPoma: review on the latest studies
Presse Med. 2023 Dec 16:104222. doi: 10.1016/j.lpm.2023.104222. Online ahead of print.ABSTRACTVasoactive intestinal peptide secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor that is characterized by watery diarrhea, hypokalemia and achlorhydria due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, electrolyte balance correction, pharmacological treatment with somatostatin analogs, surgical resection...
Source: Presse Medicale - December 18, 2023 Category: General Medicine Authors: Emija Nikola Karele Source Type: research
A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection
Endocr J. 2023 Mar 9. doi: 10.1507/endocrj.EJ22-0578. Online ahead of print.ABSTRACTVasoactive intestinal peptide-secreting tumors (VIPomas) are extremely rare functional pancreatic neuroendocrine neoplasms (p-NENs) characterized by watery diarrhea, hypokalemia, and achlorhydria. Here, we report the case of a 51-year-old female patient with VIPoma that recurred after a long-term disease-free interval. This patient had been asymptomatic for approximately 15 years after the initial curative surgery for pancreatic VIPoma, with no metastasis. The patient underwent a second curative surgery for the locally recurrent VIPoma. Who...
Source: Endocrine Journal - March 8, 2023 Category: Endocrinology Authors: Momoe Sakurai Tetsuji Wakabayashi Yasuyuki Kondo Eriko Ikeda Koichi Watanabe Akihito Takei Hiroaki Okazaki Kenta Okada Ken Ebihara Nobuyuki Kakiuchi Seishi Ogawa Noriyoshi Fukushima Shun Ishibashi Source Type: research
The VIPoma
No abstract available (Source: The Journal of Trauma: Injury, Infection, and Critical Care)
Source: The Journal of Trauma: Injury, Infection, and Critical Care - November 1, 2022 Category: Orthopaedics Tags: WTA PRESIDENTIAL ADDRESS 2022 Source Type: research
Peptide Receptor Radionuclide Therapy
J Clin Endocrinol Metab. 2022 Oct 5:dgac574. doi: 10.1210/clinem/dgac574. Online ahead of print.ABSTRACTThe concept of using a targeting molecule labeled with a diagnostic radionuclide for using PET or SPECT imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide is named "theranostics". Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well...
Source: The Journal of Clinical Endocrinology and Metabolism - October 5, 2022 Category: Endocrinology Authors: Johannes Hofland Tessa Brabander Frederik A Verburg Richard A Feelders Wouter W de Herder Source Type: research
Peptide Receptor Radionuclide Therapy
J Clin Endocrinol Metab. 2022 Oct 5:dgac574. doi: 10.1210/clinem/dgac574. Online ahead of print.ABSTRACTThe concept of using a targeting molecule labeled with a diagnostic radionuclide for using PET or SPECT imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide is named "theranostics". Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well...
Source: The Journal of Clinical Endocrinology and Metabolism - October 5, 2022 Category: Endocrinology Authors: Johannes Hofland Tessa Brabander Frederik A Verburg Richard A Feelders Wouter W de Herder Source Type: research
A case of VIPoma
A VIPoma is a rare neuroendocrine tumour secreting vasoactive intestinal peptide (VIP) that has an incidence of 1 per 10 million per year.1 Vasoactive intestinal peptide causes cardiovascular instability due to its vasodilatory effect on splanchnic and peripheral vascular beds. Direct gut effects of VIP lead to increased secretion of intestinal fluids, resulting in a syndrome of watery diarrhoea, achlorhydria, intestinal ileus, skin flushing and metabolic acidosis.2,3 It is associated with several electrolyte disturbances including hypokalaemia, hypophosphataemia, hypomagnesaemia, and hypercalcaemia. (Source: International...
Source: International Journal of Obstetric Anesthesia - September 28, 2022 Category: Anesthesiology Authors: L. Crawford, V. Amin Tags: Case Report Source Type: research
